iBio, Inc. (NASDAQ: IBIO) reported its second‑quarter fiscal 2026 results on February 10, 2026. The company posted a net loss of $0.09 per share, missing the consensus estimate of $0.0842 per share, and generated no revenue for the three months ended December 31, 2025, compared with a $0.2 million revenue in the same period a year earlier.
Research and development expenses climbed to $4.3 million, up from $1.9 million in the prior year, reflecting intensified investment in its AI‑driven antibody discovery platform and the acceleration of preclinical programs IBIO‑600 and IBIO‑610. General and administrative costs rose to $5.2 million, largely driven by a $2.5 million impairment of the IBIO‑101 intangible asset, which the company described as a write‑down of a discontinued research effort.
Cash, cash equivalents, and debt‑security investments totaled $52.7 million as of December 31, 2025. The company also completed a $26 million private placement on January 9, 2026, with net proceeds of approximately $24.4 million received in January. The infusion extends the cash runway into the third quarter of fiscal 2028, providing a financial cushion for the next phase of clinical development.
Management highlighted progress in its obesity and cardiometabolic pipeline. Chief Executive Officer Martin Brenner noted that IBIO‑600, a myostatin antibody, is nearing the end of toxicology studies and is slated for a Phase 1a trial in the first half of 2026, while IBIO‑610, an activin E antibody, is preparing for human trials in early 2027. Brenner emphasized that the new capital will accelerate these milestones and support the company’s broader AI platform strategy.
Analysts had projected a revenue of roughly $34 million for the quarter, a figure that the company did not meet, underscoring the pre‑revenue nature of its business. The earnings miss aligns with expectations for a company that is still investing heavily in research and has yet to generate commercial sales.
The combination of a financing that extends the runway, continued investment in a differentiated AI platform, and the advancement of two key preclinical candidates positions iBio to pursue its long‑term goal of delivering transformative therapies for obesity and cardiometabolic disease, despite the current quarterly loss.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.